<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2208">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05132413</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1701-III-310</org_study_id>
    <nct_id>NCT05132413</nct_id>
  </id_info>
  <brief_title>A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer</brief_title>
  <official_title>A Phase 3, Randomized Double-blind, Placebo-controlled, Multicenter Study of SHR-1701 in Combination With Bevacizumab and Chemotherapy in Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer With EGFR Mutation After Failure of TKIs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate efficacy and safety of SHR-1701 in combination with bevacizumab and chemotherapy in&#xD;
      advanced or metastatic non-squamous non-small-cell lung cancer with EGFR mutation after&#xD;
      failure of TKIs&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SHR-1701/ Placebo Plus Chemotherapy With or Without Bevacizumab</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs), serious adverse events (SAEs), and immune-related adverse events (irAEs) as per NCI-CTC AE 5.0 （Stage I）</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>BIRC-assessed progression-free survival (PFS) as per RECIST v1.1（Stage II）</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)（Stage I）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)（Stage I）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) （Stage I）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) （Stage I）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) （Stage I）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)（Stage II）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)（Stage II）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)（Stage II）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) （Stage II）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) （Stage II）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (AEs), serious adverse events （Stage II）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(SAEs), and immune-related adverse events (irAEs) as per NCI-CTC AE 5.0（Stage II）</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">561</enrollment>
  <condition>Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab</intervention_name>
    <description>SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin</intervention_name>
    <description>Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin</description>
    <arm_group_label>Placebo group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin</intervention_name>
    <description>Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin</description>
    <arm_group_label>Placebo group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        A subject must satisfy all of the following criteria to be considered for inclusion in the&#xD;
        study:&#xD;
&#xD;
          1. Histologically or cytologically confirmed advanced or metastatic non-squamous&#xD;
             non-small cell lung cancer.&#xD;
&#xD;
          2. Failed with prior EGFR-TKIs treatments.&#xD;
&#xD;
          3. Measurable disease, as defined by RECIST v1.1&#xD;
&#xD;
          4. The Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          5. Life expectancy ≥ 3 months&#xD;
&#xD;
          6. Adequate hematologic and end-organ function as defined in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        A subject who meets any of the following criteria will be excluded from study entry:&#xD;
&#xD;
          1. Histologically or cytologically confirmed mixed SCLC and NSCLC.&#xD;
&#xD;
          2. Symptomatic, untreated or active central nervous system metastases.&#xD;
&#xD;
          3. Systemic therapy with immunosuppressive agents within 2 weeks prior to initiation of&#xD;
             study treatment&#xD;
&#xD;
          4. With any active autoimmune disease or history of autoimmune disease.&#xD;
&#xD;
          5. Inadequately controlled hypertension.&#xD;
&#xD;
          6. Tumour infiltration into the great vessels on imaging.&#xD;
&#xD;
          7. History of haemoptysis ≥2.5ml per episode within 1 month prior to initiation of study&#xD;
             treatment.&#xD;
&#xD;
          8. Uncontrolled tumour-related pain.&#xD;
&#xD;
          9. Patients with active hepatitis B or hepatitis C&#xD;
&#xD;
         10. Severe infections within 4 weeks prior to initiation of study treatment. Active&#xD;
             tuberculosis within one year prior to initiation of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuanchao Wang</last_name>
    <phone>0518-81220278</phone>
    <email>yuanchao.wang@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>You Li</last_name>
    <phone>0518-81220278</phone>
    <email>you.li.yl1@hengrui.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

